



**ASX & Media Release**

## **Cleansing Notice**

**Perth, Australia; 10 February 2026:** Patrys Limited (ASX: **PAB**, “**Patrys**” or the “**Company**”), gives this notice pursuant to Section 708A(5)(e) of the Corporations Act 2001 (Cth) (“**Corporations Act**”).

The Company advises that it has issued 466,666 Shares (“**Shares**”) in the capital of the Company, per the Appendix 2A dated 10 February 2026.

### **Section 708A(5)(e) Notice – Issue of Shares without a Disclosure Document**

In accordance with the requirements of Section 708A(5)(e) of the Corporations Act, under which notice is given, the Company confirms that:

1. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act; and
2. as at the date of this notice, the Company has complied with:
  - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - b. Section 674 and Section 674A of the Corporations Act.

As at the date of this notice, there is no information to be disclosed which is excluded information (as defined in Section 708A(7) of the Corporations Act) which is required to be disclosed by the Company in accordance with Section 708A(8) of the Corporations Act.

**-Ends-**

This announcement is authorised for release by the Board of Directors of Patrys Limited.

### **For further information, please contact:**

#### **General enquiries**

Peter Christie  
Non-Executive Chair  
P: + 61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

#### **Registered Office Address**

168 Stirling Highway  
Nedlands WA, 6009

#### **About Patrys Limited**

Patrys (ASX:PAB) is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. More information can be found at [www.patrys.com](http://www.patrys.com).